Cosentyx: which tox species, and why?

“Secukinumab crossreacts with cynomolgus, rhesus and marmoset monkey IL-17A, but not with rodent IL-17A, making the cynomolgus monkey the most appropriate nonclinical species.”

“Secukinumab crossreacts with cynomolgus, rhesus and marmoset monkey IL-17A, but not with rodent IL-17A, making the cynomolgus monkey the most appropriate nonclinical species.”

“A murine surrogate antibody against mouse IL-17A (BZN035) was developed and used for fertility and early embryonic development and peri- and postnatal development studies in mice.”

“Secukinumab crossreacts with cynomolgus, rhesus and marmoset monkey IL-17A, but not with rodent IL-17A, making the cynomolgus monkey the most appropriate nonclinical species.”

“Single-dose and repeat-dose toxicity and embryofetal development studies have been conducted with the cynomolgus monkey. A murine surrogate antibody against mouse IL-17A (BZN035) was developed and used for fertility and early embryonic development and peri- and postnatal development studies in mice.”

“No genetic toxicity or carcinogenicity studies have been conducted with secukinumab.”

“A murine surrogate antibody against mouse IL-17A (BZN035) was developed and used for fertility and early embryonic development and peri- and postnatal development studies in mice.”